Xeloda (capecitabine) potentialities in the treatmentof cancer patients (review)


Cite item

Full Text

About the authors

N F Orel

РОНЦ им. Н. Н. Блохина РАМН

РОНЦ им. Н. Н. Блохина РАМН

References

  1. Schmoll Н. J. 20"'-century approaches to CRC therapy. In: Abstracts TP activation: convenience through innovation. 17 March 2001 Frankfurt. 6-8.
  2. Toi M., Ohashi Т., Takatsuka Y. et al. Selective effect of adjuvant 5'-deoxy-5-fluoridine (5'-DFUR) tumors in primary breast cancer. Proc. ASCO 1997; 16: 136a, abstr. 481.
  3. Takebayashi Y., Akiyama S., Akiba S. et al. Clinicopathologic and prognostic significance of an angiogenic factor, thymidine phosphorilase, in human colorectal carcinoma. J. Natl. Cancer Inst. 1996; 88: 1110-1117.
  4. Takebayashi Y., Maiyadera K., Akiyama S. et al. Expression of thymidine phosphorylase in human gastric carcinoma. JpnJ. Cancer Res. 1996; 87: 288-295.
  5. Mizutani Y., Okada Y., Yoshida O. et al. Expression of plateletderived endothelial cell growth factor in bladder carcinoma. Cancer 1997; 79: 1190-1194.
  6. Reynolds K., Farzanech F., Collins W. P. et al. Association of ovarian malignancy with expression of platelet-derived endothelial cell growth factor. J. Natl. Cancer lnstr. 1994; 86: 1234-1238.
  7. Imazano Y., Takebayashi Y., Nishiyama K. et al. Correlation between thymidine phosphorylase expression and prognosis in human renal cell carcinoma. J. Clin. Oncol. 1997; 15: 2570- 2578.
  8. Moghaddam A., Zhang H-T, Fan T-PD. et al. Thymidine phosphorylase is angiogenic and promotes tumor growth. Proc. Natl. Acad. Sci. USA 1995; 92; 998-1002.
  9. Matsuura Т., Kuratate L, Teramachi K. et al. Thymidine phosphorylase expression is associated with both increase of intratumoral microvessels and decrease of apoptosis in human colorectal carcinoma. Cancer Res. 1999; 59: 5037-5040.
  10. Daneuberg K., Metzger R., Grosheu S. et al. Thymidilate synthetase and thymidine phosphorylase are prognostic, indica- tions of survival for colorectal cancer. Proc. ASCO 1997; 16: 257a, abstr. 914.
  11. Гарин A.M. Новые анти метаболиты в онкологической практике. В кн.: Горбунова В. А. (ред.) Новые цитостатики в лечении злокачественных опухолей. М: 1998. 41-60.
  12. Schuller J., Cassidy J., Dumont E. et al. Preferential activation of capecitabine in tumor following oral administration in colorectal cancer patients. Cancer Chemother. Pharmacol. 2000; 45: 291-297.
  13. Ishikawa Т., Yamamoto Т., Fukase Y. et al. Antitumor activities of capecitabine much more effective than 5-FU in either monotherapy or combination therapy with standard cytostatics in human xenografts. Res. Rep. J., 1915; 146: 404.
  14. Sawada N., Ishirawa Т., Ishitsura H. Antitumor activity of capecitabine in combination with taxol or taxotere in human cancer xenografts. Ibid. 1996; 146: 551.
  15. Sawada N., Ishikawa Т., Sekiguchi F. et al. Clin. Cancer Res. 1998; 4: 1013-1014.
  16. Cao S., Hapke G., Rustum Y. M. Enhanced antitumor activity of Xeloda by irinotecan in nude mice bearing human A253 and FaDu head and neck xenografts. Ibid. 2001; 20: 42, abstr. 464.
  17. Ichikawa Т., Sawada N., Sekiquchi F. et al. Xeloda (capecitabine) a new oral fluoropyrimidine carbamate with an improved efficacy profile over other fluoropyrimidines. Ibid. 1997; v. 16, ab. 796.
  18. Yamashita K., Tsunoda Т., Urakami A. et al. Induction of thymidilate phosphorylase activity and enhancement of capecitabine efficacy by mitomycin С in human colorectal cancer. Ibid. 2001; 20: 151a, N 600.
  19. Velves C, Budman D. R., Creaven P. J. et al. Pharmacokinetics and pharmacodynamics of capecitabine in two phase studies. Ibid. 1996; 15: 467a.
  20. Туторов С. Л., Семенов Н. Н., Загрекова Е. И. Новые лекарства в лечении солидных опухолей. Рус. мед. жури. 2001; 9 (22): 1017-1020.
  21. Blum J. L., Jones S. E. Buzdar A. U. et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastases breast cancer. J. Clin. Oncol. 1999; 17: 485-493.
  22. Leonard R. С. F. Oral fluoropyrimidines among the new drugs for patients with metastatic breast cancer. Br. J. Cancer 2001; 84(11): 1437-1442.
  23. O'Reilly S. M., Moiseyenko V., Talbot D. С A randomized phase II study of Xeloda (capecitabine) vs paclitaxel in breast cancer patients failing previous anthracycline therapy. Proc. ASCO 1998; 163a, N 627.
  24. Aapro M. First-line capecitabine treatment for metastatic breast cancer: Update data from a randomized phase II trial. In: Proc. ICACT2000. 4-10.
  25. Reichardt P., von Minckwitz G, Luck H. Y. et al. Capecitabine: The new standard in metastatic breast cancer failing anthracycline and taxanes-containing chemotherapy? Mature results of a large multicenter phase II trial. Eur. J. Cancer 2001; 37 (suppl. 7): 191, N 699.
  26. Fumoleau P., Largillier R., Trillet-Lenoir V. et al. Capecitabine (Xeloda) in patients with advanced breast cancer, previously treated with anthracyclines and taxanes: results of a large phase II study. Proc. ASCO 2002; 21 (1): 62a, N 247.
  27. Prouk L., Vasey P. A., Sparreboom A. et al. A phase I and pharmacokinetis study of the combination of capecitabine and docetaxel in patients with advanced solid tumours. Br. J. Can- cer 2000; 83: 22-29.
  28. O'Shaughnessu J., Vukelja S., Moiseyenko V. et al. Results of a large phase III trial of Xeloda / Taxotere combination therapy vs Taxotere monotherapy in metastatic breast cancer patients. In: San Antonio breast cancer symposium. 2000. abstr. 381.
  29. Perez-Manga G, Batsistra N., Constenia M. et al. Efficacy and safety profile of capecitabine (Xeloda) in combination with paclitaxel in patients with locally advanced or metastatic breast cancer: preliminary results of a phase II study. Breast Cancer Res. Treat. 2000; 64: 125, abstr. 535.
  30. Angiolini C, Venturini M., DellMastro L. et al. Capecitabine in association with epirubicin and docetaxel as first line chemo- therapy in advanced breast cancer: a dose-finding study. Breast Cancer Res. Treat. 2000; 64: 123, abstr. 529.
  31. Venturini M., Del Mastro L., Durando A. et al. TEX (Taxotere, Epirubicin and Xeloda) regimen as first line chemotherapy in advanced breast cancer. A multicenter fhase II study. Proc. ASCO 2001; 20 (p. 2): 48b.
  32. Nole F., Catania C, Mandala M. et al. Phase I study of vinorelbine and capecitabine in advanced breast cancer. Breast Cancer Res. Treat. 2000; 64: 125, abstr. 539.
  33. Ahn J. H., Kim В., Lee J. S. et al. Phase II study of a combination chemotherapy of capecitabine and vinorelbine in metastatic breast cancer with previous exposure to anthracycline and taxanes: preliminary results. Proc. ASCO 2002; 21 (p. 2): 55b, N 2030.
  34. Donaldson L. A., Jenings C. L., Lee F. С et al. A phase I/I J study of carboplatin, vinorelbine and capecitabine in patients with metastatic breast cancer. Ibid. 2000; 19, 37b, N 1960.
  35. Domenech G., Perez A., Vogel C. Vinorelbine / Capecitabine (VINOCAP) combination Remission Induction Therapy for Metastatic Breast cancer. Ibid. 2001; 20 (p. 2): 48b, N 1939.
  36. Ghosn M., Farhat F., Kattan J. Vinorelbine (navelbine) IV and capecitabine (VINOCAP) as front line chemotherapy in metastatic breast cancer. Ibid. 2002; 21 (p. 2): 42b, N 1978.
  37. Bonnefoi H., Biganzoli L., Mauriac L. et al. An EORTC-IDB- BC phase I study of cyclophosphamide and epirubicin in com- bination with capecitabine (CEX) as primary treatment of locally advanced / inflammatory or large operable breast cancer. Ibid. 2001; 20 (p. 2); 13b, N 1800.
  38. Chan S. C, Wong L. N., Chow L. W. С A phase II study on an all-oral regimen of capecitabine (Xeloda), idarubicin and cyclophosphamide for metastatic breast cancer - safety, efficacy and quality of life. Ibid. 2002; 21 (p. 2): 53b, N 2023.
  39. Jakob A., Schupp M., Knop S. et al. A phase II study of capecitabine in patients who relapsed after high dose chemo therapy followed by peripheral blood stem cell transplantation for metastatic breast cancer. Ibid. 2001; 20 (p. 2): 55b, N 1966.
  40. Hoff P. Capecitabine as first-line treatment for colorectal cancer (CRC): Integrated results of 1207 patients from 2 randomized phase III study. On behalf of the capecitabine (Xeloda) CRC study group. Ann. Oncol. 2000: 11 (suppl. 4): 60, N 263.
  41. Padzur R., Douillard J. Y., Skillings J. R. et al. Multicenter phase III study of 5-fluorouracil of UFT in combination with leucovorin in patients with metastatic colorectal cancer. Proc. ASCO 1999; 18: 263a, abstr. 1009.
  42. Schmoll H. J. Putting the oral fluoropyrimidines into perspective. In: Abstracts Tnird International, conference "Perspectives in colorectal cancer. A consensus meeting". Dublin; 2001. 117-118.
  43. Kovcin V., Krivokapic Z., Jesic R. First line capecitabine (Xeloda) chemotherapy for metastatic colorectal cancer. Int. J. Cancer 2002; (suppl. 13): 273, 228s.
  44. Koudo Y., Takemiya S., Sakamoto J. et al. A multicenter phase II trial of capecitabine (Xeloda) in previously untreated advanced / metastatic colorectal cancer. Proc. ASCO 2002; 21 (p. 2): 127b, N 2322.
  45. Kerr D. Perspectives in combination therapy. Xeloda plus irinotecan. In: Abstracs Third International conference "Perspectives in colorectal cancer. A consensus meeting". Dublin; 2001. 123-125.
  46. Cassata A., Chiara S. S., Alu M. et al. Ongoing phase II trial with two schedules of irinotecan (CPT-11 in combination with capecitabine as first line chemotherapy in patients with advanced colorectal cancer. Proc. ASCO 2001; 20 (p. 1): 144, N 573.
  47. Kerr D. J., Ten W. W., Bokkel Huinink et al. A phase I/II study CPT-11 in combination with capecitabine as first line chemotherapy for metastatic colorectal cancer. Ibid. 2002; 21 (p. 1): 161a, N 643.
  48. Schleucher N., Tewes M., Achterrath W. et al. Extended phase I study of capecitabine in combination with a weekly schedule of irinotecan as first-line chemotherapy in metastatic colorectal cancer. Ibid. 2001; 20 (p. 1): 141a, N 561.
  49. Joedan K., Grothey A., Kellner O. et al. Randomized phase II trial of capecitabine plus irinotecan vs capecitabine plus oxaliplatin as first-line therapy in advanced colorectal cancer: results of an interim analysis. Ibid. 2002; 21 (p. 2); 103 b, N 2225.
  50. Evans J., Tabernero J., Cassidy J. et al. Safety profile and preliminary efficacy of capecitabine (Xeloda) in combination with oxalipiatin in patients with advances or metastatic solid tumours: results from a phase I study. Ann. Oncol. 2000; 11 (suppl. 4): 51, abstr. 2.
  51. Schoffeski P. Perspective in combination therapy. Xeloda plus oxalipiatin. In: Abstracts Third International conference "Perspectives in colorectal cancer. A consensus meeting". Dublin; 2001. 121-122.
  52. DeSantis S., Zeuli M., Di Castanzo F. et al. Oxalipiatin and capecitabine in advanced colorectal cancer: a dose-finding trial. Proc. ASCO 2001; 20 (p. 1): 141, abstr. 9.
  53. Thomas R., Quinn M., Wilson R. et al. A phase I trial of capecitabine and oxalipiatin. Ibid. 133, abstr. 530.
  54. Borner M. M., Mueller S., Roth A. et al. Phase II study of capecitabine + oxalipiatin in first line and second line treatment of advanced or metastatic colorectal cancer. Ibid. 137, abstr. 546.
  55. Sastre J., Butts C, Cassidy J. et al. Capecitabine - oxalipiatin combination (XELOX), effective Iя line therapy for patients with metastatic colorectal cancer: survival update of an international phase II trial. Ann. Oncol. 2002; 13 (suppl. 4): 80, N 288P.
  56. Tabernero J., Butts С A., Cassidy J. et al. Capecitabine and oxalipiatin in combination (Xelox) as first line therapy for patients with metastatic colorectal cancer: results of an interna- tional multicenter phase II trial. Proc. ASCO 2002; 21 (p. 1): 133a, N 531.
  57. Shields A. F., Zalupski M. M., Marshall J. L. et al. A phase II trial of oxalipiatin and capecitabine in patients with advanced colorectal cancer, (bid. 143a, N 568.
  58. Glynne-Jones R. Perspectives in combination therapy. Xeloda plus radiotherapy. In: Abstracts Third International conference "Perspectives in colorectal cancer. A consensus meeting". Dublin; 2001. 127-128.
  59. Reese Т., Tanner J., Frings S. et al. Capecitabine combined with simultaneous radiotherapy in rectal cancer: a phase I study. Int. J. Radiat. Oncol. Biol. Phys. 2000; 48 (suppl. 3): 120, abstr. 20.
  60. Dunst J., Ruse Т., Frings S. Phase I study of capecitabine combined with simultaneous radiotherapy rectal cancer. Proc. AS- CO 2001; 20 (p. l):149a, N 592.
  61. Androulakis N., Kouroussis C, Kakolyris S. et al. Phase I study of capecitabine combinatior wit radiotherapy as adjuvant treatment for operable rectal cancer. Ibid. 2002; 21 (p. 2): 121 b, N 2297.
  62. Huller D. G. New approaches to adjuvant therapy for colorectal cancer. In: Abstracts Third International Conference "Perspectives in colorectal cancer. A consensus meeting". Dublin; 2001. 107-111.
  63. Lee F. С, Wong G. Capecitabine and mitomycin C for AIDS patients with anal squamous cell carcinoma. Proc. ASCO 2002; 21 (p. 2): 144b, N 2389.
  64. Cunningham D., James R. D. Integrating the oral fluoropyrimidines into the management of advanced colorectal cancer. Eur.J. Cancer 2001; 37: 826-834.
  65. Koizumi W., Taguchi T. A. A phase II study of capecitabine (Xeloda) in patients with advanced metastatic gastric carcinoma. Proc. ASCO 2001; 20: 142b, N 2320.
  66. Hdng Y., Song S., Cho J. et al. A phase II trial of capecitabine (Xeloda) in chemotherapy naive patients with advanced and/or metastatic gastric cancer. Ibid. 2002; 21 (p. 1): 156a, N 623.
  67. Базип И. С, Гарин А. М. Рак желудка: значение проблемы и современные возможности лечения. Рус. мед. журн. 2002; 10 (4): 588-593.
  68. Kim Т., Ahn J., Lee J. et al. A phase II trial of capecitabine and cisplatin in previously untreated advanced gastric cancer. Proc. ASCO 2001; 20: 166a, N 662.
  69. Evans T. R. J., Paul J., Mclnnes A. et al. Final results of a phase I and PK study of capecitabine (Xeloda) in combination with epirubicin and cisplatin in patients with advanced oesophagogastric adenocarcinoma. Eur. J. Cancer 2001; 37 (suppl. 6); 312, N 1156.
  70. Tebbutt /V., Norman A., Cunningham D. et al. Ramdomised, multicenter phase III comparing capecitabine with fluorour- acil and oxaliplatin with cisplatin in patients with advanced oesophago-gastric cancer: interim analysis. Proc. ASCO 2002; 21 (p. I): 131a, N 523.
  71. Karim А. В., Hallem F., Sayeed F. S. et al. Combination chemotherapy for advanced Gl-adenocarcinoma combining with CPT-11 and capecitabine: a pilot study in Bangladesh. Ibid. (p.2): 139b, N 2371.
  72. Delord J. P., Pierga J. Y., Dieras V. et al. Dose escalating and pharmacokinetic study of capecitabine (Xeloda) and irinotecan (CPT-11) in gastro-intestinal tumors preliminary results. Ibid. (p. I): 100a, N 397.
  73. Kennedy A. S., Van Echo D. A., Volpe С et al. Phase I studies using capecitabine combined with conformal radiation therapy, paclitaxel, CPT-11 and celecoxib in gastrointestinal melagnancies. Ibid. (p. 2): 300b, N 3021.
  74. Merin J. M., Lee F. С Palliative benefit for salvage treatment with capecitabine and thalidomide for gastric and / or esophageal adenocarcinoma: a retrospective case series. Ibid. 144b, N2391.
  75. Kim T. W., Ahn J. H., Chang H. M. et al. A phase II trial of capecitabine and cisplatin in previously untreated advanced billiary cancer. Ibid. 115b, N 2273.
  76. Anthony L. В., Matthews E., Cronin M. et al. Continuous lowedose capecitabine produces significant biochemical responses in patients with progressive gastoentetopancreatic neoplasms. Ibid. 2001; 20 (p. 2): 104b, N 2167.
  77. Cartwright T. A phase II trial of Xeloda (capecitabine) in advanced or metastatic pancreatic cancer. Ibid. 2000; 19: 264a, abstr. 1026.
  78. Herrmann R., Borner M., Morant R. et al. Combining gemcitabine and capecitabine in advanced pancreatic cancer. Results of a phase I trial. Ibid. 267a, N 1038.
  79. Scheithauer W., Schull В., Ulrich-Pur H. et al. Gemcitabine alone or in combination with capecitabine in patients with advanced pancreatic adenocarcinoma. Ibid. 2002; 21 (p. 1): 126a, N 500.
  80. Hess V., Bomer M., Morant R. et al. Gemcitabine and capecitabine for advanced pancreatic cancer. A phase I//II trial. Eur.J. Cancer 2001; 37 (suppl. 6).: s. 315, N 1167.
  81. Campos L. Т., Alvarez R-, Sanford D. et al. Gemcitabine and capecitabine in advanced pancreatic cancer in solid tumors. A single institution experience. Proc. ASCO 2001; 20 (p. 2): 141b, N 2315.
  82. Schilsky R. L., Bertucci D., Vogelzang N. J. et al. Doseescalating study of capecitabine plus gemcitabine combination therapy in patients with advanced cancer. J. Clin. Oncol. 2002; 20: 582-587.
  83. Vasey P. A., McMahon L., Paur J. et al. A phase II trial of capecitabine (Xeloda) in relapsed ovarian cancer. Ann. Oncol. 2000; 11 (suppl. 4): 84, abstr. 373.
  84. Overmann K, Buer J., Hoffman R. et al. Capecitabine in the treatment of metastatic renal cell carcinoma. Br. J. Cancer 2000; 83: 583-587.
  85. Akhtar S. U., Mathew P., Lin J. et al. Phase II trial of capecitabine and carboplatin in patients with newly diagnosed advanced non-small cell carcinoma of the lung. Proc ASCO 2001; 20: 278b, N 2862.
  86. Pivot X., Chamorey E., Guardiola E. et al. Phase I accelerated dose escalating and pharmacokinetic study of capecitabine and cisplatin in head and neck cancer patients. Ibid. 2002; 21: 108a, N 428.
  87. Porta R., Carbonell X., del Campo M. J. et al. Phase I study of capecitabine in combination with cisplatin in patients with advancec and / or metastatic squamous cell carcinoma of the head and neck. Ibid. 239a, N 953.
  88. Van Echo D. A., Kennedy A. S., Sutharalingam M. Phase 1 studies of Xeloda plus chemotherapy and radiation in head/ neck or gastrointestinal cancer. Int. J. Cancer 2002; (suppl. 13): 426, p928.
  89. Sykes A., Slevin N. A phase I study to determine the maximun tolerated dose of capecitabine when given concurrently with radical radiotherapy in the treatment of squamous cell carcinoma of the head and neck. Proc. ASCO 2002; 21: 253a, N 936.
  90. Wenzel C, Schmidinger M. P., Locker G. J. et al. Oral chemotherapy with capecitabine (Xeloda) in the treatment of metastatic renal cancer falling immunotherapy. Ibid. 2000; 19: 368a, N 1457.
  91. Wenzel С. С, Schmidinger M. P., Locker G. J. et al. Capecitabine in the treatment of metastatic renal cell carcinoma failng immunotherapy - the Vienna Experience. Ibid. 2001; 20: 196a, N 782.
  92. Wenzel C, Locker G. J., Bonkoe T. et al. Pilot study of capecitabine in combination with immunotherapy in the treatment of metastatic renal cell carcinoma. Ibid. 2002; 21: 148b, N 2404.
  93. Morant R. H. J., Dietrich D., Gillessen S. et al. Capecitabine in hormonerefractory metastatic prostate cancer: a phase II trial of the SAKK. Ibid. (p. 2): 157b, N 2442.
  94. Hirawat S., Kolitz J., Lichtman S. et al. Squential irinotecan and capecitabine (Xeloda) given every other week in the management of advanced metastatic carcinoma: a phase I study. Ibid. 79b, N 2127.
  95. Szatrowski T. P., Barau R. W., Shaw J. et al. Palliative treatment opportunities for geriatric oncology patients in longterm care: advantage of oral chemotherapy agents such as capecitabine (Xeloda). Ibid. 260b, N 2857.
  96. Proccopio G, Bajetta E., Catena L. et al. Safety and activity of Capecitabine in elderly patients with advanced breast cancer.Eur. J. Cancer 2001; 37 (suppl. 6): s. 197, N 720.
  97. Monfardini S. Medical oncology in cancer in the elderly. Ibid. (suppl.7): s. 253, N 255.
  98. Van Custem E. A in-depth analysis of Xeloda incolorectal cancer studies: what more can we learn? In: Abstracts Tird International Conference "Perspectives in colorectal cancer. A consensus meeting". Dublin; 2001. 119-120.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2003 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


Согласие на обработку персональных данных с помощью сервиса «Яндекс.Метрика»

1. Я (далее – «Пользователь» или «Субъект персональных данных»), осуществляя использование сайта https://journals.rcsi.science/ (далее – «Сайт»), подтверждая свою полную дееспособность даю согласие на обработку персональных данных с использованием средств автоматизации Оператору - федеральному государственному бюджетному учреждению «Российский центр научной информации» (РЦНИ), далее – «Оператор», расположенному по адресу: 119991, г. Москва, Ленинский просп., д.32А, со следующими условиями.

2. Категории обрабатываемых данных: файлы «cookies» (куки-файлы). Файлы «cookie» – это небольшой текстовый файл, который веб-сервер может хранить в браузере Пользователя. Данные файлы веб-сервер загружает на устройство Пользователя при посещении им Сайта. При каждом следующем посещении Пользователем Сайта «cookie» файлы отправляются на Сайт Оператора. Данные файлы позволяют Сайту распознавать устройство Пользователя. Содержимое такого файла может как относиться, так и не относиться к персональным данным, в зависимости от того, содержит ли такой файл персональные данные или содержит обезличенные технические данные.

3. Цель обработки персональных данных: анализ пользовательской активности с помощью сервиса «Яндекс.Метрика».

4. Категории субъектов персональных данных: все Пользователи Сайта, которые дали согласие на обработку файлов «cookie».

5. Способы обработки: сбор, запись, систематизация, накопление, хранение, уточнение (обновление, изменение), извлечение, использование, передача (доступ, предоставление), блокирование, удаление, уничтожение персональных данных.

6. Срок обработки и хранения: до получения от Субъекта персональных данных требования о прекращении обработки/отзыва согласия.

7. Способ отзыва: заявление об отзыве в письменном виде путём его направления на адрес электронной почты Оператора: info@rcsi.science или путем письменного обращения по юридическому адресу: 119991, г. Москва, Ленинский просп., д.32А

8. Субъект персональных данных вправе запретить своему оборудованию прием этих данных или ограничить прием этих данных. При отказе от получения таких данных или при ограничении приема данных некоторые функции Сайта могут работать некорректно. Субъект персональных данных обязуется сам настроить свое оборудование таким способом, чтобы оно обеспечивало адекватный его желаниям режим работы и уровень защиты данных файлов «cookie», Оператор не предоставляет технологических и правовых консультаций на темы подобного характера.

9. Порядок уничтожения персональных данных при достижении цели их обработки или при наступлении иных законных оснований определяется Оператором в соответствии с законодательством Российской Федерации.

10. Я согласен/согласна квалифицировать в качестве своей простой электронной подписи под настоящим Согласием и под Политикой обработки персональных данных выполнение мною следующего действия на сайте: https://journals.rcsi.science/ нажатие мною на интерфейсе с текстом: «Сайт использует сервис «Яндекс.Метрика» (который использует файлы «cookie») на элемент с текстом «Принять и продолжить».